T. Rowe Price Investment Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,418,145 shares of ALNY stock, worth $1.4 Billion. This represents 0.79% of its overall portfolio holdings.
Number of Shares
4,418,145
Previous 4,384,449
0.77%
Holding current value
$1.4 Billion
Previous $1.03 Billion
15.63%
% of portfolio
0.79%
Previous 0.64%
Shares
11 transactions
Others Institutions Holding ALNY
# of Institutions
718Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.29 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.12 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.01 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.26 Billion0.44% of portfolio
-
Baillie Gifford & CO3.66MShares$1.15 Billion0.89% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $38.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...